Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Women First to market Fournier's Esclim in US:

This article was originally published in Clinica

Executive Summary

Women First HealthCare is to market the French company Groupe Fournier's FDA-approved oestradiol transdermal patch in the US. The Esclim patch is manufactured by Fournier's drug delivery subsidiary, Cross Site, based in Dijon, France. It is approved in 20 countries and is brand leader in France. The company claims it has the widest dosage options of any twice-weekly patch currently available in the US, where the transdermal patch market is estimated at $170 million. San Diego, California-based Women First develops and markets products aimed at menopausal women.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT079061

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel